Photo of Michael Ross

Michael Ross

  • ASSOCIATE PROFESSOR Medicine, Nephrology
Print ProfilePrint Profile



  • Nephrology

  • American Board of Internal Medicine


  • MD, New York University

  • Residency, Internal Medicine
    Duke University Hospital

  • Fellowship, Renal Disease
    Mount Sinai Hospital


    Dr. Michael Ross, MD, received his Bachelor of Science degree from Tufts University in 1991 and his Medical degree from New York University in 1995.  After completing a residency in Internal Medicine at Duke University in 1998, Dr. Ross did his Nephrology fellowship training at Mount Sinai and subsequently joined the faculty in the Division of Nephrology in 2001.  Dr. Ross has been Director of the Nephrology Fellowship Program, one of the largest and most successful programs in the US, since 2004 and recently became Chief of Nephrology at the James J. Peters VA Medical Center in 2014.  Dr. Ross also has an NIH-funded laboratory where he leads studies into the mechanisms of HIV-associated kidney diseases and is actively engaged in clinical and translational research.  Dr. Ross holds leadership positions on national research and medical education committees and is currently Deputy Editor of Kidney International, one of the leading Nephrology research journals.


Pathogenesis of HIV-related kidney diseases

HIV-infected patients are at increased risk of several types of acute and chronic kidney disease, including HIV-associated nephropathy (HIVAN), immune complex glomerulonephritis, and acute kidney injury (AKI).  The mechanisms by which HIV-1 infection predisposes to renal injury is not well understood but direct infection of renal epithelial cells and dysregulation of renal epithelial genes have important roles in renal pathogenesis.  Our laboratory uses a variety of in vitro molecular methods and transgenic and knockout animal models to study how viral proteins and host factors  contribute to HIV-associated kidney diseases.

Mechanisms by which antiretroviral medications protect and/or harm kidneys

Though combination antiretroviral therapy (cART) is efficacious in preventing and treating HIV-associated nephropathy (HIVAN), the mechanisms by which these medications protect the kidney from the deleterious effects of HIV are poorly understood.  Moreover, some ART agents, including tenofovir, can cause kidney injury in some patients.  We are therefore  performing studies using innovative animal models and molecular techniques to identify novel pathways by which ART can protect and/or injury the kidney.


Ross MJ, Klotman PE, Winston JA. HIV-associated nephropathy: case study and review of the literature. AIDS Patient Care and STDs 2000; 14(12): 637-45.

Ross MJ, Bruggeman LA, Wilson PW, Klotman PE. Microcyst formation and HIV-1 gene expression occur in multiple nephron segments in HIV-associated nephropathy. J Am Soc Nephrol 2001; 12(12): 2645-51.

Klotman PE. Recent progress in HIV-associated nephropathy [review]. J Am Soc Nephrol 2002 Dec; 13(12): 2997-3004.

Kaufman L, Hayashi K, Ross MJ, Ross MD, Klotman PE. Sidekick-1 is upregulated in glomeruli in HIV-associated nephropathy. J Am Soc Nephrol 2004 Jul; 15(7): 1721-30.

Ross M, Klotman PE. HIV-associated nephropathy. AIDS 2004 May 21; 18(8): 1089-99.

Ross MJ, Martinka S, D'Agati VD, Bruggeman LA. NF-kappaB regulates Fas-mediated apoptosis in HIV-associated nephropathy. J Am Soc Nephrol 2005 Aug; 16(8): 2403-11.

Lu TC, Ross M. HIV-associated nephropathy: a brief review. Mt Sinai J Med 2005 May; 72(3): 193-9.

Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005 Aug; 16(8): 2412-20.

Leventhal JS, He JC, Ross MJ. Autophagy and immune response in kidneys. Seminars in nephrology 2014 Jan; 34(1).

Ryom L, Mocroft A, Kirk O, Ross M, Reiss P, Fux CA, Morlat P, Moranne O, Smith C, El-Sadr W, Law M, Lundgren JD. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS (London, England) 2014 Jan; 28(2).

Lucas GM, Cozzi-Lepri A, Wyatt CM, Post FA, Bormann AM, Crum-Cianflone NF, Ross MJ. Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals. HIV medicine 2014 Feb; 15(2).

Kamara DA, Ryom L, Ross M, Kirk O, Reiss P, Morlat P, Moranne O, Fux CA, Mocroft A, Sabin C, Lundgren JD, Smith CJ. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. BMC nephrology 2014; 15.

Jin Y, Ratnam K, Chuang PY, Fan Y, Zhong Y, Dai Y, Mazloom AR, Chen EY, D'Agati V, Xiong H, Ross MJ, Chen N, Ma'ayan A, He JC. A systems approach identifies HIPK2 as a key regulator of kidney fibrosis. Nature medicine 2012 Apr; 18(4).

Ganesan A, Krantz EM, Huppler Hullsiek K, Riddle MS, Weintrob AC, Lalani T, Okulicz JF, Landrum M, Agan B, Whitman TJ, Ross MJ, Crum-Cianflone NF. Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care. HIV medicine 2013 Feb; 14(2).

Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. The Journal of infectious diseases 2013 May; 207(9).

Alsauskas ZC, Medapalli RK, Ross MJ. Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients. Expert opinion on pharmacotherapy 2011 Apr; 12(5).

Chen P, Chen BK, Mosoian A, Hays T, Ross MJ, Klotman PE, Klotman ME. Virological synapses allow HIV-1 uptake and gene expression in renal tubular epithelial cells. Journal of the American Society of Nephrology : JASN 2011 Mar; 22(3).

Mallipattu SK, Ross MJ. Methotrexate in the urine. Kidney international 2011 Jul; 80(2).

Mocroft A, Neuhaus J, Peters L, Ryom L, Bickel M, Grint D, Koirala J, Szymczak A, Lundgren J, Ross MJ, Wyatt CM. Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PloS one 2012; 7(7).

Snyder A, Alsauskas Z, Gong P, Rosenstiel PE, Klotman ME, Klotman PE, Ross MJ. FAT10: a novel mediator of Vpr-induced apoptosis in human immunodeficiency virus-associated nephropathy. Journal of virology 2009 Nov; 83(22).

Gong P, Canaan A, Wang B, Leventhal J, Snyder A, Nair V, Cohen CD, Kretzler M, D'Agati V, Weissman S, Ross MJ. The ubiquitin-like protein FAT10 mediates NF-kappaB activation. Journal of the American Society of Nephrology : JASN 2010 Feb; 21(2).

Snyder A, Alsauskas ZC, Leventhal JS, Rosenstiel PE, Gong P, Chan JJ, Barley K, He JC, Klotman ME, Ross MJ, Klotman PE. HIV-1 viral protein r induces ERK and caspase-8-dependent apoptosis in renal tubular epithelial cells. AIDS (London, England) 2010 May; 24(8).

Neuhaus J, Jacobs DR, Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. The Journal of infectious diseases 2010 Jun; 201(12).

Leventhal JS, Alsauskas Z, Snyder A, Gong P, Wang B, D'Agati V, Ross MJ. Renal HIV expression is unaffected by serum LPS levels in an HIV transgenic mouse model of LPS induced kidney injury. PloS one 2011; 6(6).

Chen P, Chen BK, Mosoian A, Hays T, Ross MJ, Klotman PE, Klotman ME. Virological synapses allow HIV-1 uptake and gene expression in renal tubular epithelial cells. Journal of the American Society of Nephrology : JASN 2011 Mar; 22(3).

Ross MJ. Advances in the pathogenesis of HIV-associated kidney diseases. Kidney international 2014 Aug; 86(2).

Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, Atta MG, Wools-Kaloustian KK, Pham PA, Bruggeman LA, Lennox JL, Ray PE, Kalayjian RC. Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014 Nov; 59(9).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Ross did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central


Annenberg Building Floor 23rd Floor Room Room 40
1468 Madison Avenue
New York, NY 10029


Annenberg Building Floor 23 Room 4D
1468 Madison Avenue
New York, NY 10029


Annenberg Building Floor 23rd Floor Room Room 4D
1468 Madison Avenue
New York, NY 10029

Tel: 212-241-0131
Fax: 212-987-0389